NewLimit CEO: AI is Biotech's Biggest Shift in 40+ Years
jacobkimmel · x · 2026-09-02
Jacob Kimmel, Co-Founder and CEO of NewLimit, states that AI is the first revolution in biopharma on the same scale as recombinant DNA technology. He predicts that firms developing models to design molecules will partner with pharma companies to create medicines that previously could not have existed.
More from Companies & People
- Hacktoberfest 2026 Shifts From Open-Source Contributions to Open AI Community Events — jonmarkgo · 2026-09-02
- Broadcom's VMware Private AI Push Signals Enterprise AI Moving From Pilots to Production — DavidLinthicum · 2026-09-02
- UT PGE Faculty Discuss AI Strategy for Teaching and Research — GeostatsGuy · 2026-09-02
- Meta's Return to AI Front Rank: Strategy and Stats — rohanpaul_ai · 2026-09-02
- Berkeley professor joins TransluceAI as senior research fellow — 2plus2make5 · 2026-09-02
- Pentium chip father Vinod Dham discusses AI and longevity — Chris_Armstrong · 2026-09-02